DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0154278 A1 Brody Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0154278 A1 Brody Et Al US 2006O154278A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0154278 A1 Brody et al. (43) Pub. Date: Jul. 13, 2006 (54) DETECTION METHODS FOR DISORDERS (60) Provisional application No. 60/477,218, filed on Jun. OF THE LUNG 10, 2003. (75) Inventors: Jerome S. Brody, Newton, MA (US); Publication Classification Avrum Spira, Newton, MA (US) (51) Int. C. Correspondence Address: CI2O I/68 (2006.01) Ronald I. Eisenstein, Esq. G06F 9/00 (2006.01) NXON PEABODY LLP (52) U.S. Cl. ................................................... 435/6; 702/20 100 Summer Street Boston, MA 02110 (US) (57) ABSTRACT (73) Assignee: The Trustees of Boston University, Bos The present invention is directed to prognostic and diagnos ton, MA tic methods to assess lung disease risk caused by airway Appl. No.: 11/294,834 pollutants by analyzing expression of one or more genes (21) belonging to the airway transcriptome provided herein. (22) Filed: Dec. 6, 2005 Based on the finding of a so called “field defect” affecting the airways, the invention further provides a minimally Related U.S. Application Data invasive sample procurement method in combination with the gene expression-based tools for the diagnosis and prog (63) Continuation of application No. PCT/US04/18460, nosis of diseases of the lung, particularly diagnosis and filed on Jun. 9, 2004. prognosis of lung cancer. Patent Application Publication Jul. 13, 2006 Sheet 2 of 42 US 2006/0154278 A1 10']>Jml,dll/MdTSNTSWHIMSENEJJOISIT d Patent Application Publication Jul. 13, 2006 Sheet 4 of 42 US 2006/0154278 A1 o y qe96ZZIZ Patent Application Publication Jul. 13, 2006 Sheet 6 of 42 US 2006/0154278 A1 zevecs'0|| 8/9980°0 GIZI69°0 SOTE00*0 svo600,0 689800’0 8£0000'0 OZGZOOWIN 619?.00WIN 092€.00WN 966200WIN Patent Application Publication Jul. 13, 2006 Sheet 7 of 42 US 2006/0154278 A1 V,±0IJI Patent Application Publication Jul. 13, 2006 Sheet 9 of 42 US 2006/0154278 A1 Patent Application Publication Jul. 13, 2006 Sheet 10 of 42 US 2006/0154278 A1 GT3°5)I,HI Patent Application Publication Jul. 13, 2006 Sheet 11 of 42 US 2006/0154278 A1 Patent Application Publication Jul. 13, 2006 Sheet 12 of 42 US 2006/0154278 A1 „H3'50IJI Patent Application Publication Jul. 13, 2006 Sheet 13 of 42 US 2006/0154278 A1 93“OICH Patent Application Publication Jul. 13, 2006 Sheet 14 of 42 US 2006/0154278 A1 DBS258 NON-SMOKER 600 TUMOR 400 N (LOHRATIO = 64) 200 SIZE 147.84 HEIGH 22 600 NON-MALIGNANTLUNG 400 2OO SIZE 147.85 HEIGHT HEIGHT 752 626 BOO SMOKER SOO TUMOR 400 (LOHRATIO = .99) 200 SIZE 149.77 HEIGHT HEIGHT 943 615 900 NON-MALIGNANT LUNG 600 300 SIZE SIZE 149.77 151.73 Example of LOH analysis. The panels are the electropherograms resulting from the amplification of the DNA templates from tumor and nonmalignant lung tissue (normal). Allelic loss was calculated using a normalized allele height ratio (LOH ratio) equation in which R= (A1)(N2)/(A2) (N1) where A1 and A2 are the heights of the alleles from lung and N1 and N2 are the heights of the alleles from the DNA from normal tissue. For informative primers, LOH was scored as a 20% decrease in the height ratio of an allele inadenocarcinoma Compared with the height ratio of the same allele in nonmalignant lung DNA. Therefore, cases in which the LOHRatio was <0.8 or >1.25 were scored as LOH. The horizontal axis is allele size in base pairs. The Vertical axis is the allele height in arbitrary fluorescent units. In this example, the tumor tissue from the nonsmoker (top panel, arrow) demonstrates LOH at the microSatellite D8S258. Patent Application Publication Jul. 13, 2006 Sheet 15 of 42 US 2006/0154278 A1 3. 5SE5 e s E3: s s N s Se s Ps S S (TV) SSO)ITTYTYNOLION Patent Application Publication Jul. 13, 2006 Sheet 17 of 42 US 2006/0154278 A1 crocesoroctocaecaeocaeocaecaeoeaedes-Beroeaecroesroer»erbo-perocrocrocroeae |}| {{9(9.I.H. Patent Application Publication Jul. 13, 2006 Sheet 18 of 42 US 2006/0154278 A1 O O O O s | |?olo || ofLI INNsIYY. | | | | | Ovu I NI V | | | | O | A OF YW. S. PIE 56p W|W | | || 1 || O d 9 WYY EIIL's N. |PPPP | | | IAIHO9) EO V Idigy| s 2 g Patent Application Publication Jul. 13, 2006 Sheet 19 of 42 US 2006/0154278 A1 2 S O Patent Application Publication Jul. 13 2006 Sheet 20 of 42 US 2006/0154278 A1 Patent Application Publication Jul. 13, 2006 Sheet 21 of 42 US 2006/0154278 A1 1OOOOO 5 10000 1000 e 2 100 2 2 10 E R=92 0.1 0.1 1 10 1OO 1000 1 OOOO 100000 GENE EXPRESSION INTENSITY (RIGHT BRONCHUS) 100000 2 10000 2 e S2 1000 E E 100 5 10 5 R=85 0.1 0.1 1 1O 1OO 1OOO 1OOOO 10OOOO GENE EXPRESSION INTENSITY (BASELINE) FIG. 8B Patent Application Publication Jul. 13, 2006 Sheet 22 of 42 US 2006/0154278 A1 - REPLICATESAMPLES - - - - UNRELATED SAMPLES ANALYSISOFREPLICATESAMPLES WERSUSUNRELATED SAMPLES 0.0008 O.OOO 0.0006 O.0004 0.0003 O.OOO2 FOLD CHANGE (log2(DIFFERENTIAL GENE EXPRESSIONRATIO) FIG. 8C Patent Application Publication Jul. 13, 2006 Sheet 24 of 42 US 2006/0154278 A1 NORMAL AIRWAY TRANSCRIPTOME (7119 GENES) 1400 1200 1000 TOP 10% MOST WARIABLE GENES 400 200 O 50 100 150 200 COEFFICIENT OF WARIATION (Sd/mean)*100) FIG. 10 Patent Application Publication Jul. 13, 2006 Sheet 25 of 42 US 2006/0154278 A1 153F/20 156F/20 126F/2 136F/1.08 159F/12 138F/12 77F/7 53F/32 63F/12 52F/27 144F/20 122F/1.17 119F/O.67 34F/20 78F/O.5 134F/1 108F/O.25 163F/008 FIG. 11 Patent Application Publication Jul. 13, 2006 Sheet 26 of 42 US 2006/0154278 A1 NQO1 EXPRESSION REAL-TIMERT-PCR MICROARRAY 12.00 10.00 8.00 6.00 R=.98 4.00 i 2.00 O.OO % 143N 149N 145N 146C 140C 162C SAMPLE # FIG, 12A ALDH3A1 EXPRESSION REAL-TIMERT-PCR TOOO MICROARRAY 60.00 50.00 40.00 30.00 20.00 i 10.00 OOO 143N 149N 145N 146C 140C 162C SAMPLE # FIG. I2B Patent Application Publication Jul. 13, 2006 Sheet 27 of 42 US 2006/0154278 A1 REAL-TIMERT-PCR CYP1B1 EXPRESSION MICROARRAY 400.00 350.00 300.00 250.00 200.00 150.00 1OO.OO i 50.00 O.OO 143N 149N 145N 146C 14OC 162C SAMPLE # FIG. 12C CEACAM5 EXPRESSION 60.00 REAL-TIMERT-PCR MICROARRAY 50.00 40.00 30.00 20.00 i 10.00 O.OO 143N 149N 145N 146C 14OC 162C SAMPLE # FIG. 12D Patent Application Publication Jul. 13, 2006 Sheet 28 of 42 US 2006/0154278 A1 REAL-TIMERT-PCR SLT1 EXPRESSION MICROARRAY 2.00 1.OO s O.OO 2 -1.00 g -2.00 S -3.00 R=. 95 -4.00 m 2 -5.00 -6.00 154 159 (F 156 (F 163 (F 18O (N) quitd quitd quit.< (S) 2 yrs 2 yrs 2 yrs ago) ago) ago) SAMPLE # FIG. 12E Patent Application Publication Jul. 13, 2006 Sheet 29 of 42 US 2006/0154278 A1 AFFYMETRIX ID GENE 207847 s at muc-1TRANSMEMBRANE 204895 X at muc-4 213693 s at muC-1 TRANSMEMBRANE 214303 X at muc-5 AC 214385 s at muc-5B 217 109 at muc-4 21711.0 s at muc-4 205725 at CLARA CEL 209008 X at CYTOKERATIN 8 FIG. 13 Patent Application Publication Jul. 13, 2006 Sheet 30 of 42 US 2006/0154278 A1 AFFYMETRIX ID GENE (CELLTYPE SPECIFICITY) 205049 s at cd-79 alpha (BCELL) 205297 s at cd-79 beta (BCELL) 205264 at cd-3EPSILONASSOCIATED PROTEIN(TCELL) 210031 at cd-3 Zeta (TCELL) 206804 at cd-3 gamma (TCELL) 205982 X at SURFACTANTASSOCIATED PROTEINC (DISTALALYEOLAREPTHELIUM) 211735 X at SURFACTANTASSOCIATED PROTEINC(DISTALALVEOLAREPTHELIUM) 214199 at SURFACTANTASSOCIATED PROTEIND(DISTALALVEOLAREPTHELIUM) 21.8835 at SURFACTANTASSOCIATED PROTEIN A2(DISTALALVEOLAR EPITHELIUM) 215454 x at SURFACTANTASSOCIATED PROTEINC(DISTALALVEOLAREPITHELIUM) 203948 s at MPO (MYELOID/MONOCYTE) 203949 at MPO (MYELOID/MONOCYTE) 206120 at CD33(MYELOID SPECIFIC) 210184 at CD11c(MYELOID SPECIFIC) 204625 s at CD61 (MEGAKARYOCYTE) 211579 at CD61 (MEGAKARYOCYTE) FIG. 14 Patent Application Publication Jul. 13, 2006 Sheet 31 of 42 US 2006/0154278 A1 NEVER FORMER cuRRENT PVALUE METHOD NUMBER OF SUBJECTS 23 18 W 34 AGE 54.33 (16.64) 43.59 (12.23) ANOVA GENDER 11M/7F 27M/7F CHISO RACE 7W/19B/80 CHISQ PACK YEARS OFSMOKING 22.02 (20.30) ITEST: AGE STARTED SMOKING 19.12 (12.01) LENGTH OF TIMESMOKED (YRS) 25.18 (17.56). 24.24 (13.70) TIME PASSED SINCEQUIT (YRS)NA 10.49 (10.47) NA FIG. 15 MEAN R SAMPLES SQUARED ALL REPLICATES (TECHNICAL SPATIAL TEMPORAL, N=7) N (N=23, #PAIRWISE CORRELATIONS=253) CURRENTSMOKERS (N=34, #PAIRWISE CORRELATIONS=561) CURRENT VERSUSNEVER SMOKERS (#PAIRWISE CORRELATIONS = 782) FIG. 16 Patent Application Publication Jul. 13, 2006 Sheet 33 of 42 US 2006/0154278 A1 AFFYMETRIX A GE: GENDER: D GENE VARIABLE AGE GENDER RACE GENDER RACE MODEL 204211 X AT PRKR 2.25E-04 1.64E-05 8.82E-05 217933 SAT LAP3 2.41E-04 1.71E-06 | 1.40E-05 214001 X AT RPS10 2.86E-04 2.16E-06 || 4.25E-05 201883 SAT B4GALT1 3.01E-04 3.22E-06 9.00E-05 209969 SAT STAT1 3.23E-04 2.2E-03 1.12E-06 | 1.84E-05 209696 AT FBP1 4.09E-04 6.63E-04 1.86E-03 3.99E-04 217738 AT PBEF 9.61E-04 .19E-05 || 7.42E-04 208018 S AT HCK 1.62E-03 5.62E-05 4.76E-04 201426 SAT RPLP2 1.68E-03 1.OE-03 634E-04 218.986 SAT FU20035 1.75E-03 1.57E04 2.14E-03 214315X AT CALR 2.03E-03 8.91E-06 1.62E-04 202446.
Load more

Recommended publications
  • Refinement and Discovery of New Hotspots of Copy-Number Variation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ARTICLE Refinement and Discovery of New Hotspots of Copy-Number Variation Associated with Autism Spectrum Disorder Santhosh Girirajan,1,5 Megan Y. Dennis,1,5 Carl Baker,1 Maika Malig,1 Bradley P. Coe,1 Catarina D. Campbell,1 Kenneth Mark,1 Tiffany H. Vu,1 Can Alkan,1 Ze Cheng,1 Leslie G. Biesecker,2 Raphael Bernier,3 and Evan E. Eichler1,4,* Rare copy-number variants (CNVs) have been implicated in autism and intellectual disability. These variants are large and affect many genes but lack clear specificity toward autism as opposed to developmental-delay phenotypes. We exploited the repeat architecture of the genome to target segmental duplication-mediated rearrangement hotspots (n ¼ 120, median size 1.78 Mbp, range 240 kbp to 13 Mbp) and smaller hotspots flanked by repetitive sequence (n ¼ 1,247, median size 79 kbp, range 3–96 kbp) in 2,588 autistic individuals from simplex and multiplex families and in 580 controls. Our analysis identified several recurrent large hotspot events, including association with 1q21 duplications, which are more likely to be identified in individuals with autism than in those with developmental delay (p ¼ 0.01; OR ¼ 2.7). Within larger hotspots, we also identified smaller atypical CNVs that implicated CHD1L and ACACA for the 1q21 and 17q12 deletions, respectively. Our analysis, however, suggested no overall increase in the burden of smaller hotspots in autistic individuals as compared to controls. By focusing on gene-disruptive events, we identified recurrent CNVs, including DPP10, PLCB1, TRPM1, NRXN1, FHIT, and HYDIN, that are enriched in autism.
    [Show full text]
  • Metallothionein Monoclonal Antibody, Clone N11-G
    Metallothionein monoclonal antibody, clone N11-G Catalog # : MAB9787 規格 : [ 50 uL ] List All Specification Application Image Product Rabbit monoclonal antibody raised against synthetic peptide of MT1A, Western Blot (Recombinant protein) Description: MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Immunogen: A synthetic peptide corresponding to N-terminus of human MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Host: Rabbit enlarge Reactivity: Human, Mouse Immunoprecipitation Form: Liquid Enzyme-linked Immunoabsorbent Assay Recommend Western Blot (1:1000) Usage: ELISA (1:5000-1:10000) The optimal working dilution should be determined by the end user. Storage Buffer: In 20 mM Tris-HCl, pH 8.0 (10 mg/mL BSA, 0.05% sodium azide) Storage Store at -20°C. Instruction: Note: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. Datasheet: Download Applications Western Blot (Recombinant protein) Western blot analysis of recombinant Metallothionein protein with Metallothionein monoclonal antibody, clone N11-G (Cat # MAB9787). Lane 1: 1 ug. Lane 2: 3 ug. Lane 3: 5 ug. Immunoprecipitation Enzyme-linked Immunoabsorbent Assay ASSP5 MT1A MT1B MT1E MT1F MT1G MT1H MT1M MT1L MT1IP Page 1 of 5 2021/6/2 Gene Information Entrez GeneID: 4489 Protein P04731 (Gene ID : 4489);P07438 (Gene ID : 4490);P04732 (Gene ID : Accession#: 4493);P04733 (Gene ID : 4494);P13640 (Gene ID : 4495);P80294 (Gene ID : 4496);P80295 (Gene ID : 4496);Q8N339 (Gene ID : 4499);Q86YX0 (Gene ID : 4490);Q86YX5
    [Show full text]
  • PCDHGC3 (NM 032403) Human Tagged ORF Clone Lentiviral Particle – RC211429L4V | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC211429L4V PCDHGC3 (NM_032403) Human Tagged ORF Clone Lentiviral Particle Product data: Product Type: Lentiviral Particles Product Name: PCDHGC3 (NM_032403) Human Tagged ORF Clone Lentiviral Particle Symbol: PCDHGC3 Synonyms: PC43; PCDH-GAMMA-C3; PCDH2 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) ACCN: NM_032403 ORF Size: 402 bp ORF Nucleotide The ORF insert of this clone is exactly the same as(RC211429). Sequence: OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_032403.1 RefSeq Size: 2326 bp RefSeq ORF: 405 bp Locus ID: 5098 UniProt ID: Q9BR81 Protein Families: Transmembrane MW: 13.9 kDa This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 PCDHGC3 (NM_032403) Human Tagged ORF Clone Lentiviral Particle – RC211429L4V Gene Summary: This gene is a member of the protocadherin gamma gene cluster, one of three related clusters tandemly linked on chromosome five.
    [Show full text]
  • Protein Interaction Network of Alternatively Spliced Isoforms from Brain Links Genetic Risk Factors for Autism
    ARTICLE Received 24 Aug 2013 | Accepted 14 Mar 2014 | Published 11 Apr 2014 DOI: 10.1038/ncomms4650 OPEN Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism Roser Corominas1,*, Xinping Yang2,3,*, Guan Ning Lin1,*, Shuli Kang1,*, Yun Shen2,3, Lila Ghamsari2,3,w, Martin Broly2,3, Maria Rodriguez2,3, Stanley Tam2,3, Shelly A. Trigg2,3,w, Changyu Fan2,3, Song Yi2,3, Murat Tasan4, Irma Lemmens5, Xingyan Kuang6, Nan Zhao6, Dheeraj Malhotra7, Jacob J. Michaelson7,w, Vladimir Vacic8, Michael A. Calderwood2,3, Frederick P. Roth2,3,4, Jan Tavernier5, Steve Horvath9, Kourosh Salehi-Ashtiani2,3,w, Dmitry Korkin6, Jonathan Sebat7, David E. Hill2,3, Tong Hao2,3, Marc Vidal2,3 & Lilia M. Iakoucheva1 Increased risk for autism spectrum disorders (ASD) is attributed to hundreds of genetic loci. The convergence of ASD variants have been investigated using various approaches, including protein interactions extracted from the published literature. However, these datasets are frequently incomplete, carry biases and are limited to interactions of a single splicing isoform, which may not be expressed in the disease-relevant tissue. Here we introduce a new interactome mapping approach by experimentally identifying interactions between brain-expressed alternatively spliced variants of ASD risk factors. The Autism Spliceform Interaction Network reveals that almost half of the detected interactions and about 30% of the newly identified interacting partners represent contribution from splicing variants, emphasizing the importance of isoform networks. Isoform interactions greatly contribute to establishing direct physical connections between proteins from the de novo autism CNVs. Our findings demonstrate the critical role of spliceform networks for translating genetic knowledge into a better understanding of human diseases.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • PCDHGC3 (NM 032402) Human Tagged ORF Clone Lentiviral Particle Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC211379L3V PCDHGC3 (NM_032402) Human Tagged ORF Clone Lentiviral Particle Product data: Product Type: Lentiviral Particles Product Name: PCDHGC3 (NM_032402) Human Tagged ORF Clone Lentiviral Particle Symbol: PCDHGC3 Synonyms: PC43; PCDH-GAMMA-C3; PCDH2 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) ACCN: NM_032402 ORF Size: 2589 bp ORF Nucleotide The ORF insert of this clone is exactly the same as(RC211379). Sequence: OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_032402.1 RefSeq Size: 2794 bp RefSeq ORF: 2592 bp Locus ID: 5098 UniProt ID: Q9UN70, Q9BR81 Domains: CA Protein Families: Transmembrane MW: 91.2 kDa This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 PCDHGC3 (NM_032402) Human Tagged ORF Clone Lentiviral Particle – RC211379L3V Gene Summary: This gene is a member of the protocadherin gamma gene cluster, one of three related clusters tandemly linked on chromosome five.
    [Show full text]
  • Integrating Single-Step GWAS and Bipartite Networks Reconstruction Provides Novel Insights Into Yearling Weight and Carcass Traits in Hanwoo Beef Cattle
    animals Article Integrating Single-Step GWAS and Bipartite Networks Reconstruction Provides Novel Insights into Yearling Weight and Carcass Traits in Hanwoo Beef Cattle Masoumeh Naserkheil 1 , Abolfazl Bahrami 1 , Deukhwan Lee 2,* and Hossein Mehrban 3 1 Department of Animal Science, University College of Agriculture and Natural Resources, University of Tehran, Karaj 77871-31587, Iran; [email protected] (M.N.); [email protected] (A.B.) 2 Department of Animal Life and Environment Sciences, Hankyong National University, Jungang-ro 327, Anseong-si, Gyeonggi-do 17579, Korea 3 Department of Animal Science, Shahrekord University, Shahrekord 88186-34141, Iran; [email protected] * Correspondence: [email protected]; Tel.: +82-31-670-5091 Received: 25 August 2020; Accepted: 6 October 2020; Published: 9 October 2020 Simple Summary: Hanwoo is an indigenous cattle breed in Korea and popular for meat production owing to its rapid growth and high-quality meat. Its yearling weight and carcass traits (backfat thickness, carcass weight, eye muscle area, and marbling score) are economically important for the selection of young and proven bulls. In recent decades, the advent of high throughput genotyping technologies has made it possible to perform genome-wide association studies (GWAS) for the detection of genomic regions associated with traits of economic interest in different species. In this study, we conducted a weighted single-step genome-wide association study which combines all genotypes, phenotypes and pedigree data in one step (ssGBLUP). It allows for the use of all SNPs simultaneously along with all phenotypes from genotyped and ungenotyped animals. Our results revealed 33 relevant genomic regions related to the traits of interest.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • PCDHGC3 (NM 032403) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC211429L4 PCDHGC3 (NM_032403) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: PCDHGC3 (NM_032403) Human Tagged ORF Clone Tag: mGFP Symbol: PCDHGC3 Synonyms: PC43; PCDH-GAMMA-C3; PCDH2 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC211429). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_032403 ORF Size: 402 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 PCDHGC3 (NM_032403) Human Tagged ORF Clone – RC211429L4 OTI Disclaimer: Due to the inherent nature of this plasmid, standard methods to replicate additional amounts of DNA in E. coli are highly likely to result in mutations and/or rearrangements. Therefore, OriGene does not guarantee the capability to replicate this plasmid DNA. Additional amounts of DNA can be purchased from OriGene with batch-specific, full-sequence verification at a reduced cost. Please contact our customer care team at [email protected] or by calling 301.340.3188 option 3 for pricing and delivery. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g.
    [Show full text]
  • Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture
    Learning from cadherin structures and sequences: affinity determinants and protein architecture Klára Fels ıvályi Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Klara Felsovalyi All rights reserved ABSTRACT Learning from cadherin structures and sequences: affinity determinants and protein architecture Klara Felsovalyi Cadherins are a family of cell-surface proteins mediating adhesion that are important in development and maintenance of tissues. The family is defined by the repeating cadherin domain (EC) in their extracellular region, but they are diverse in terms of protein size, architecture and cellular function. The best-understood subfamily is the type I classical cadherins, which are found in vertebrates and have five EC domains. Among the five different type I classical cadherins, the binding interactions are highly specific in their homo- and heterophilic binding affinities, though their sequences are very similar. As previously shown, E- and N-cadherins, two prototypic members of the subfamily, differ in their homophilic K D by about an order of magnitude, while their heterophilic affinity is intermediate. To examine the source of the binding affinity differences among type I cadherins, we used crystal structures, analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and electron paramagnetic resonance (EPR) studies. Phylogenetic analysis and binding affinity behavior show that the type I cadherins can be further divided into two subgroups, with E- and N-cadherin representing each. In addition to the affinity differences in their wild-type binding through the strand-swapped interface, a second interface also shows an affinity difference between E- and N-cadherin.
    [Show full text]
  • The Roles of Metallothioneins in Carcinogenesis Manfei Si and Jinghe Lang*
    Si and Lang Journal of Hematology & Oncology (2018) 11:107 https://doi.org/10.1186/s13045-018-0645-x REVIEW Open Access The roles of metallothioneins in carcinogenesis Manfei Si and Jinghe Lang* Abstract Metallothioneins (MTs) are small cysteine-rich proteins that play important roles in metal homeostasis and protection against heavy metal toxicity, DNA damage, and oxidative stress. In humans, MTs have four main isoforms (MT1, MT2, MT3, and MT4) that are encoded by genes located on chromosome 16q13. MT1 comprises eight known functional (sub)isoforms (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, and MT1X). Emerging evidence shows that MTs play a pivotal role in tumor formation, progression, and drug resistance. However, the expression of MTs is not universal in all human tumors and may depend on the type and differentiation status of tumors, as well as other environmental stimuli or gene mutations. More importantly, the differential expression of particular MT isoforms can be utilized for tumor diagnosis and therapy. This review summarizes the recent knowledge on the functions and mechanisms of MTs in carcinogenesis and describes the differential expression and regulation of MT isoforms in various malignant tumors. The roles of MTs in tumor growth, differentiation, angiogenesis, metastasis, microenvironment remodeling, immune escape, and drug resistance are also discussed. Finally, this review highlights the potential of MTs as biomarkers for cancer diagnosis and prognosis and introduces some current applications of targeting MT isoforms in cancer therapy. The knowledge on the MTs may provide new insights for treating cancer and bring hope for the elimination of cancer. Keywords: Metallothionein, Metal homeostasis, Cancer, Carcinogenesis, Biomarker Background [6–10].
    [Show full text]